JP2024515880A5 - - Google Patents

Info

Publication number
JP2024515880A5
JP2024515880A5 JP2023566873A JP2023566873A JP2024515880A5 JP 2024515880 A5 JP2024515880 A5 JP 2024515880A5 JP 2023566873 A JP2023566873 A JP 2023566873A JP 2023566873 A JP2023566873 A JP 2023566873A JP 2024515880 A5 JP2024515880 A5 JP 2024515880A5
Authority
JP
Japan
Prior art keywords
polypeptide
active
composition
composition according
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026998 external-priority patent/WO2022232552A1/en
Publication of JP2024515880A publication Critical patent/JP2024515880A/ja
Publication of JP2024515880A5 publication Critical patent/JP2024515880A5/ja
Pending legal-status Critical Current

Links

JP2023566873A 2021-04-30 2022-04-29 免疫応答を回避する脂質ナノ粒子治療薬 Pending JP2024515880A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182605P 2021-04-30 2021-04-30
US63/182,605 2021-04-30
PCT/US2022/026998 WO2022232552A1 (en) 2021-04-30 2022-04-29 Lipid nanoparticle therapeutics that evade the immune response

Publications (2)

Publication Number Publication Date
JP2024515880A JP2024515880A (ja) 2024-04-10
JP2024515880A5 true JP2024515880A5 (cg-RX-API-DMAC7.html) 2025-05-09

Family

ID=83848676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566873A Pending JP2024515880A (ja) 2021-04-30 2022-04-29 免疫応答を回避する脂質ナノ粒子治療薬

Country Status (7)

Country Link
US (1) US20240226310A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329816A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515880A (cg-RX-API-DMAC7.html)
CN (1) CN117425496A (cg-RX-API-DMAC7.html)
AU (1) AU2022264032A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217121A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022232552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260094503A (ko) * 2023-09-13 2026-06-22 테세라 테라퓨틱스, 인크. 치료용 페이로드를 세포에 전달하기 위한 지질 나노입자
WO2025129106A1 (en) * 2023-12-14 2025-06-19 The Trustees Of The University Of Pennsylvania Immunoevasive targeting molecules for efficient targeted delivery
WO2025166993A1 (zh) * 2024-02-05 2025-08-14 复旦大学 一种新型脂质化合物以及组合物和核酸脂质纳米颗粒制剂及其筛选方法和应用
WO2026122996A1 (en) * 2024-12-06 2026-06-11 Tessera Therapeutics, Inc. Lipid nanoparticles for delivery of therapeutic payloads to cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258698B2 (en) * 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2016145031A1 (en) * 2015-03-09 2016-09-15 Stc.Unm Cd 47 containing porous nanoparticle supported lipid bilayers (protocells)
EA201890006A1 (ru) * 2015-06-10 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Применение экзосом для лечения болезни
WO2017106380A1 (en) * 2015-12-18 2017-06-22 The Regents Of The University Of California Protein nanocapsules with detachable zwitterionic coating for protein delivery
US20190046446A1 (en) * 2016-09-30 2019-02-14 Eriochem Usa, Llc Apo-e modified lipid nanoparticles for drug delivery to targeted tissues and therapeutic methods
AU2019255765B2 (en) * 2018-04-19 2025-02-06 Board Of Regents, The University Of Texas System Therapeutic modulation of tumor suppressors using exosomes
CN110878127B (zh) * 2018-09-06 2022-06-28 浙江柏拉阿图医药科技有限公司 长效重组GLP1-Fc-CD47蛋白及其制备和用途
US20200093936A1 (en) * 2018-09-21 2020-03-26 The Trustees Of The University Of Pennsylvania Therapeutic Targeting of Lipid Nanoparticles
CN110540589B (zh) * 2019-01-08 2021-07-20 西南大学 一种多肽、多肽修饰的脂质载体及应用
US20220251200A1 (en) * 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof

Similar Documents

Publication Publication Date Title
JP5914356B2 (ja) インターフェロンアナログ
Bansal et al. Novel engineered targeted interferon‐gamma blocks hepatic fibrogenesis in mice
ES2744225T3 (es) Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
JP6416106B2 (ja) ゴナドトロピンカルボキシ末端ペプチドに結合することによりポリペプチドの流体力学的体積を増加させる方法
US8802240B2 (en) Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US20160199309A1 (en) Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
Guichard et al. PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals
JP2009519011A5 (cg-RX-API-DMAC7.html)
JP2009518025A5 (cg-RX-API-DMAC7.html)
JP2012067100A (ja) Il−21の誘導体
AU2006215566A1 (en) Insulinotropic agents conjugated with structurally well defined branched polymers
JP2025122021A5 (cg-RX-API-DMAC7.html)
JP2017503022A (ja) インビボで細胞に活性型テロメラーゼを提供する組成物および方法
Rodríguez-Castejón et al. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review
JP2021176875A (ja) ポリエチレングリコール(peg)−インターロイキン11(il−11)コンジュゲートを生成するための反応中間体、および、peg−il−11コンジュゲートを精製する方法
WO2005035565A1 (en) Il-21 derivatives
US20220202903A1 (en) Hematopoietic Growth Factor Proteins and Analogs Thereof and Angiotensin Converting Enzyme Inhibitors for Treatment of Radiation Exposure
ES2372728T3 (es) Cicatrización de heridas mediante la administración de il-18 humana.
KR102685034B1 (ko) 금속 나노 입자-핵산 결합체를 기반으로 하는 유전자 운반체
US20090054318A1 (en) Immunopotentiating Agent
CN104136038A (zh) 体腔积液抑制剂
JPH1067678A (ja) 肝疾患治療用医薬組成物
WO2024065651A1 (zh) 一种向adam10基因敲除的hek293细胞外泌体中装载二聚体cd24的方法
DE10049010A1 (de) Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
WO2025176180A1 (zh) 艾日布林衍生物药物偶联物用于治疗肿瘤的用途